CY1125885T1 - Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του - Google Patents

Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Info

Publication number
CY1125885T1
CY1125885T1 CY20231100138T CY231100138T CY1125885T1 CY 1125885 T1 CY1125885 T1 CY 1125885T1 CY 20231100138 T CY20231100138 T CY 20231100138T CY 231100138 T CY231100138 T CY 231100138T CY 1125885 T1 CY1125885 T1 CY 1125885T1
Authority
CY
Cyprus
Prior art keywords
polypeptide
fix polypeptide
modified fix
production
modified factor
Prior art date
Application number
CY20231100138T
Other languages
English (en)
Inventor
Paolo Simioni
Original Assignee
Uniqure Biopharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125885(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B.V. filed Critical Uniqure Biopharma B.V.
Publication of CY1125885T1 publication Critical patent/CY1125885T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Στο παρόν κείμενο περιλαμβάνονται ένα τροποποιημένο πολυπεπτίδιο FIX (παράγοντας IX) που περιλαμβάνει λευκίνη, κυστεΐνη, ασπαρτικό οξύ, γλουταμικό οξύ, ιστιδίνη, λυσίνη, ασπαραγίνη, γλουταμίνη ή τυροσίνη στη θέση 338 · φαρμακευτικά σκευάσματα που περιέχουν το εν λόγω τροποποιημένο πολυπεπτίδιο FIX · μια νουκλεοτιδική αλληλουχία που κωδικοποιεί το τροποποιημένο πολυπεπτίδιο FIX · και μια μέθοδο για την παραγωγή του τροποποιημένου πολυπεπτιδίου FIX.
CY20231100138T 2008-09-15 2023-03-14 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του CY1125885T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
EP09748260.8A EP2337849B1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
EP17175191.0A EP3252157A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
PCT/EP2009/061935 WO2010029178A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production

Publications (1)

Publication Number Publication Date
CY1125885T1 true CY1125885T1 (el) 2024-02-16

Family

ID=41397565

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20231100138T CY1125885T1 (el) 2008-09-15 2023-03-14 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του
CY2023016C CY2023016I2 (el) 2008-09-15 2023-07-27 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2023016C CY2023016I2 (el) 2008-09-15 2023-07-27 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Country Status (18)

Country Link
US (11) US9249405B2 (el)
EP (5) EP4032979B1 (el)
CA (1) CA2737094C (el)
CY (2) CY1125885T1 (el)
DK (2) DK3581650T3 (el)
ES (2) ES2940323T3 (el)
FI (2) FI3581650T3 (el)
FR (1) FR23C1028I1 (el)
HK (1) HK1244507A1 (el)
HR (2) HRP20230259T1 (el)
HU (2) HUE061345T2 (el)
LT (2) LT3581650T (el)
NO (1) NO2023029I1 (el)
PL (3) PL4032979T3 (el)
PT (1) PT3581650T (el)
SI (1) SI3581650T1 (el)
TR (1) TR201813067T4 (el)
WO (1) WO2010029178A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
ES2959747T3 (es) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AU2016282781A1 (en) 2015-06-23 2018-01-18 The Children's Hospital Of Philadelphia Modified Factor IX, and compositions, methods and uses for gene transfer to cells, organs and tissues
HRP20221089T1 (hr) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimizirani geni faktora viii
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
CN116732066A (zh) * 2016-10-14 2023-09-12 四川至善唯新生物科技有限公司 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
IL280637B1 (en) 2017-05-22 2024-07-01 Baxalta Inc Viral vectors encoding recombinant FIX with increased expression for gene therapy of hemophilia B
CN111344412A (zh) 2017-07-10 2020-06-26 优尼科Ip有限公司 人类中aav基因疗法的手段和方法
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
CN113164762A (zh) 2018-05-09 2021-07-23 生物马林药物股份有限公司 苯丙酮尿症的治疗方法
TW202016298A (zh) 2018-05-14 2020-05-01 美商拜奧馬林製藥公司 Aav 載體於幼年受試者中之穩定表現
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP3810770A1 (en) * 2018-08-20 2021-04-28 Ucl Business Ltd Factor ix encoding nucleotides
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US20240293516A1 (en) * 2021-07-01 2024-09-05 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
JP3553970B2 (ja) 1996-06-11 2004-08-11 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 組換え血液凝固プロテアーゼ
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
EP0971724B1 (en) 1997-02-14 2010-01-20 American Red Cross Expression of active human factor ix in mammary tissue of transgenic animals
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001070763A1 (en) 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
EP1427820A2 (en) 2001-09-04 2004-06-16 MERCK PATENT GmbH Modified factor ix
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
AU2003221733A1 (en) * 2002-04-17 2003-11-03 University Of Florida Research Foundation, Inc. Improved raav vectors
KR20100109969A (ko) 2002-10-02 2010-10-11 카탈리스트 바이오사이언시즈, 인코포레이티드 변경된 특이성을 갖는 프로테아제의 제조 및 선별 방법
EP2281877A3 (en) * 2003-05-21 2011-06-01 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
RU2396347C2 (ru) 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
DE502004008275D1 (de) 2004-08-19 2008-11-27 Gerd Baer Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
ATE549037T1 (de) * 2004-09-22 2012-03-15 St Jude Childrens Res Hospital Verbesserte expression von faktor-ix in gentherapie-vektoren
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
AU2005316476A1 (en) 2004-12-15 2006-06-22 University Of Florida Research Foundation, Inc. Chimeric vectors
ES2400306T3 (es) 2005-10-21 2013-04-09 Catalyst Biosciences, Inc. Proteasas modificadas que inhiben la activación del complemento
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
PL1969127T5 (pl) 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
US7375084B2 (en) * 2006-03-07 2008-05-20 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor IX
WO2007110231A2 (en) 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
US7588772B2 (en) * 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
EP2009990B1 (en) * 2006-04-07 2016-09-21 The Board of Regents of The University of Texas System Methods and compositions related to adenoassociated virus-phage particles
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
US20070280906A1 (en) * 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
EP2423306A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
CN104087591A (zh) 2006-06-19 2014-10-08 阿斯克肋匹奥生物制药公司 用于基因治疗的修饰的因子viii和因子ix基因和载体
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EP2108045B1 (en) * 2007-02-01 2013-12-11 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
WO2008127654A2 (en) 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CN104004739A (zh) 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ix变体
BRPI0910702A2 (pt) * 2008-04-16 2016-07-05 Bayer Healthcare Llc polipeptídeos de fator ix modificados e usos dos mesmos
CN102065887A (zh) 2008-04-16 2011-05-18 拜耳医药保健有限公司 因子ix的定点修饰
CN102105582A (zh) 2008-04-21 2011-06-22 诺沃-诺迪斯克有限公司 高糖基化人凝血因子ix
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
US8647620B2 (en) 2009-06-25 2014-02-11 The University Of North Carolina At Chapel Hill Chimeric factor VII molecules
KR20120060209A (ko) 2009-07-31 2012-06-11 바이엘 헬스케어 엘엘씨 변형된 인자 ix 폴리펩티드 및 그의 용도
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US10398787B2 (en) 2012-10-26 2019-09-03 Vrije Universiteit Brussel Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
WO2016146757A1 (en) 2015-03-17 2016-09-22 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
AU2016282781A1 (en) 2015-06-23 2018-01-18 The Children's Hospital Of Philadelphia Modified Factor IX, and compositions, methods and uses for gene transfer to cells, organs and tissues
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ix融合蛋白以及其製備及使用方法

Also Published As

Publication number Publication date
US20210238573A1 (en) 2021-08-05
EP3581650A2 (en) 2019-12-18
FIC20230026I1 (fi) 2023-07-25
HRP20181442T1 (hr) 2018-12-14
US20220002702A1 (en) 2022-01-06
FR23C1028I1 (fr) 2023-10-06
ES2940323T3 (es) 2023-05-05
PT3581650T (pt) 2023-03-08
US20160122740A1 (en) 2016-05-05
NO2023029I1 (no) 2023-07-31
PL2337849T3 (pl) 2018-11-30
ES2687038T3 (es) 2018-10-23
US9982248B2 (en) 2018-05-29
CA2737094F (en) 2010-03-18
US20200231958A1 (en) 2020-07-23
HUE061345T2 (hu) 2023-06-28
EP4219547A2 (en) 2023-08-02
EP4032979A1 (en) 2022-07-27
EP3581650A3 (en) 2020-03-25
HRP20230259T1 (hr) 2023-04-28
EP3581650B1 (en) 2022-12-28
CA2737094C (en) 2018-02-20
LT3581650T (lt) 2023-05-10
US20110244550A1 (en) 2011-10-06
SI3581650T1 (sl) 2023-06-30
DK3581650T3 (da) 2023-03-13
TR201813067T4 (tr) 2018-09-21
EP4219547A3 (en) 2023-10-18
HUS2300024I1 (hu) 2023-08-28
US10465180B2 (en) 2019-11-05
US20170355973A1 (en) 2017-12-14
US20180258413A1 (en) 2018-09-13
CY2023016I1 (el) 2024-02-16
EP2337849A1 (en) 2011-06-29
US20220090042A1 (en) 2022-03-24
US20200199564A1 (en) 2020-06-25
CA2737094A1 (en) 2010-03-18
US20200190498A1 (en) 2020-06-18
CY2023016I2 (el) 2024-02-16
US9249405B2 (en) 2016-02-02
EP4032979B1 (en) 2024-05-01
PL3581650T3 (pl) 2023-05-22
DK2337849T3 (en) 2018-10-01
US20210214704A1 (en) 2021-07-15
PL4032979T3 (pl) 2024-09-30
HK1244507A1 (zh) 2018-08-10
LTPA2023521I1 (el) 2023-08-25
EP2337849B1 (en) 2018-06-13
FI3581650T3 (fi) 2023-03-23
EP4032979C0 (en) 2024-05-01
WO2010029178A1 (en) 2010-03-18
EP3252157A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
CY1125885T1 (el) Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του
CY1118980T1 (el) Στερεες μορφες ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου
CY1112402T1 (el) Ενισχυτες υποδοχεων γλουταμικου
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
NO20063624L (no) FC region varianter
EA200700255A1 (ru) Новый карбамилированный еро и способ его получения
CY1109888T1 (el) Προφαρμακα των ενωσεων 2,4-πυριμιδινδιαμινης και οι χρησεις αυτων
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
ATE404225T1 (de) Radiofluorierte peptide
CY1114504T1 (el) Συνθεσεις τιγεκυκλινης και μεθοδοι παρασκευης
CY1118180T1 (el) Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
SE0301010D0 (sv) Novel compounds
EA201270758A1 (ru) Мутанты fgf21 и их применение
EA201990619A1 (ru) Fgf21 мутанты и их применение
TW200732866A (en) Binary sinusoidal sub-wavelength gratings as alignment marks
BRPI0606687A2 (pt) composições nutracêuticas
NO20076687L (no) Oral doseringsform
SE0301009D0 (sv) Novel compounds
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
EA200702543A1 (ru) Циклопентадиенильно-флуоренильные лиганды с углеродными мостиками
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
ATE455845T1 (de) Verfahren zur herstellung von substanzen